EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

Robina Aerts iD, Lize Cuypers, Eelco F J Meijer, Michel Kohnen, Jacques F Meis iD, Oliver A Cornely iD, Katrien Lagrou, Jon Salmanton-García iD

Mycoses · 2025

DOI: 10.1111/myc.70092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, 2025. Verfasst von Robina Aerts und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Leuven University Hospitals, Leuven, Belgium. Hauptthemen laut MEDLINE: Antifungal Agents, Drug Resistance, Fungal, Azoles, Invasive Fungal Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Invasive fungal infections (IFI) are a major clinical challenge, particularly in immunocompromised patients, and are associated with high morbidity and mortality. With the increasing prevalence of immunosuppressive conditions and ageing populations, the incidence of IFI is rising globally.

Objective

This survey aims to evaluate the diagnostic and therapeutic capacities for IFI in Belgium, the Netherlands, and Luxembourg (Benelux), a region of high azole‐resistance among Aspergillus fumigatus isolates.

Methods

A survey evaluating the diagnostic and therapeutic capacity for IFI was conducted in the Benelux. Data were collected from specialists via an online case report form between March and September 2023. The survey addressed patient characteristics, access to microbiology labs, diagnostic methods (microscopy, culture, molecular diagnostics, etc.), IFI incidence, and the availability of antifungal drugs and therapeutic drug monitoring.

Results

In total, 32 hospitals responded to the questionnaire (12 [38%] from the Netherlands, 19 [59%] from Belgium and one [3%] from Luxembourg). Antifungal susceptibility tests were available in 29 institutions (91%), constituting 84% of the centres in Belgium and 100% for the Netherlands ( p = 0.265). Aspergillus PCR testing was available in 12 centres in Belgium (63%) while in 11 centres in the Netherlands (92%, p = 0.108). Mucorales PCR testing was available in 56% of centres. Treatment with at least one amphotericin B formulation was only available in 84% of the responding centres. Therapeutic drug monitoring (TDM), although recommended, was possible for voriconazole in 26 centres (81%) while for posaconazole in 24 centres (75%). Significantly more testing (diagnostic tests and TDM) was outsourced in Belgium compared to the Netherlands ( p < 0.001).

Conclusions

Antifungal susceptibility testing is widely available in Belgium and the Netherlands, but implementation in areas with high azole resistance for Aspergillus fumigatus is not yet universal, and techniques vary. Tests for coinfections, like Mucorales PCR, were only available in half of the centres. More testing is outsourced in Belgium, likely due to differences in reference centre organisation, country size, transport, and reimbursement. Delays in diagnosis can impact patient outcomes, so awareness of test availability and transport times is crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsDrug Resistance, FungalAzolesInvasive Fungal InfectionsHumansNetherlandsBelgiumLuxembourgAspergillus fumigatusMicrobial Sensitivity TestsSurveys and QuestionnairesMaleFemaleMiddle AgedAdultAgedIncidenceDrug Monitoring

Stichwörter der Autor:innen

antifungal resistanceaspergillus antigenazole‐resistanceinvasive aspergillosisinvasive fungal infectionslateral flow assayslateral flow devicesmycology

Substanzen

Antifungal AgentsAzoles

Autor:innen und Institutionen

  • Department of Haematology, Leuven University Hospitals, Leuven, Belgium.
  • Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • KU Leuven, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, Leuven, Belgium.
  • Department of Laboratory Medicine, National Reference Centre for Rotavirus, University Hospitals of Leuven, Leuven, Belgium.
  • Department of Medical Microbiology and Immunology, Canisius-Wilhelmina Hospital (CWZ)/Dicoon, Nijmegen, the Netherlands.
  • Radboudumc-CWZ Center of Expertise for Mycology, Nijmegen, the Netherlands.

ORCID-Profile: Robina Aerts, Jacques F Meis, Oliver A Cornely, Jon Salmanton-García

Zitieren

APA

Aerts, R., Cuypers, L., Meijer, E. F. J., Kohnen, M., Meis, J. F., Cornely, O. A., Lagrou, K., & Salmanton-García, J. (2025). ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance. Mycoses. https://doi.org/10.1111/myc.70092

Vancouver

Aerts R, Cuypers L, Meijer EFJ, Kohnen M, Meis JF, Cornely OA, et al. ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance. Mycoses. 2025. doi:10.1111/myc.70092

BibTeX
@article{Aerts2025,
  author = {Aerts, Robina and Cuypers, Lize and Meijer, Eelco F J and Kohnen, Michel and Meis, Jacques F and Cornely, Oliver A and Lagrou, Katrien and Salmanton-García, Jon},
  title = {ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance},
  journal = {Mycoses},
  year = {2025},
  doi = {10.1111/myc.70092}
}
Kostenlos starten →